ETF exposure
Sprint 56All ETFs holding this ticker — weight, shares, and flow-of-funds impact.
Citable ownership snapshot
CVS's latest 13F holder table lists Citadel Advisors as the largest holder in this view with 10,099,243 shares valued at $725.33M.
| Holder | Report date | Value | Portfolio weight |
|---|---|---|---|
| Citadel Advisors | Mar 31, 2026 | $725.33M | 0.1% |
| D.E. Shaw & Co. | Mar 31, 2026 | $184.03M | 0.1% |
| AQR Capital Management | Mar 31, 2026 | $169.64M | 0.1% |
| Millennium Management | Mar 31, 2026 | $126.80M | 0.1% |
| Balyasny Asset Management | Mar 31, 2026 | $106.78M | 0.1% |
| Bridgewater Associates | Mar 31, 2026 | $44.42M | 0.2% |
| Renaissance Technologies | Mar 31, 2026 | $18.90M | 0.0% |
| Point72 Asset Management | Mar 31, 2026 | $13.65M | 0.0% |
Source: SEC EDGAR 13F filings; period Mar 31, 2026; filed May 15, 2026.
Continue research
Follow same-sector companies and source explainers connected to the ownership view.
A factual guide to 13F filings, what they show, what they omit, and how Aerarium Research turns them into holder and overlap views.
A factual guide to Schedule 13D and 13G beneficial ownership reports for holders with more than 5% stakes.
A factual guide to definitive proxy statements, shareholder voting matters, board information, and executive compensation disclosures.
A factual guide to Form 4 — who must file, what insider buys and sells disclose, and why a single transaction rarely explains itself.